Nexturastat A

CHF 160.00
In stock
AG-CR1-3901-M0011 mgCHF 160.00
AG-CR1-3901-M0055 mgCHF 640.00
More Information
Product Details
Synonyms 4-((1-Butyl-3-phenylureido)methyl)-N-hydroxybenzamide
Product Type Chemical
Properties
Formula

C19H23N3O3

MW 341.4
CAS 1403783-31-2
Purity Chemicals ≥98% (HPLC)
Appearance Light pink solid.
Solubility Soluble in DMSO. Slightly soluble in methanol or ethanol (1mg/ml). Almost insoluble in water.
Identity Determined by 1H-NMR.
InChi Key JZWXMCPARMXZQV-UHFFFAOYSA-N
Smiles CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC1=CC=CC=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =5.02nM). Displays high selectivity over all other HDACs (IC50=3-10µM).
  • Suppresses cell proliferation and promotes apoptosis in B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of α-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation.
  • Induces cell cycle arrest in G1.
  • HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Product References
  1. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth: J.A. Bergman, et al.; J. Med. Chem. 55, 9891 (2012)
  2. Development and therapeutic implications of selective histone deacetylase 6 inhibitors: J.H. Kalin & J.A Bergman; J. Med. Chem. 56, 6297 (2013)
  3. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation: K.V. Woan, et al.; Mol. Oncol. 9, 1447 (2015)
  4. Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy: L. Zhang, et al.; Med. Res. Rev. 35, 63 (2015) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.